Cathepsin K inhibitors suppressed breast cancer-mediated osteolysis and breast cancer cell invasiveness [86], and odanacatib (MK-0822), one of the cathepsin K inhibitors, decreased bone turnover markers in a phase II clinical trial of breast cancer bone metastasis [178]. Here, CTSK is linked to breast carcinoma.